Epidyolex 100 mg/ml oral solution clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex (EpiCom)
This study looks at how a medicine called Epidyolex affects behaviour and other common issues in children and young people (1-65 years old) with Tuberous Sclerosis Complex (TSC) who experience seizures. It's an add-on treatment.
For: Tuberous Scerlosis ComplexPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures
This study looks at a medicine called Epidyolex for young children with Dravet Syndrome, Tuberous Sclerosis Complex, or Lennox-Gastaut Syndrome. It checks if the medicine is safe, how much stays in the body, and if it helps reduce seizures. This is a big final-stage study.
For: Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut SyndromeItaly · Spain - AuthorisedTherapeutic exploratory (Phase II)
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
This study looks at whether a cannabis-based medicine called Epidyolex can help children and teenagers with severe learning difficulties who hurt themselves. We want to see if it reduces how often they self-injure over about two months.
For: Children and adolescents with severe neurodevelopmental disordersFrance